The global Thromboprophylactic Drug market size is expected to reach $ 47448 million by 2032, rising at a market growth of 4.7% CAGR during the forecast period (2026-2032).
Thromboprophylactic Drug refers to a category of anticoagulant or antiplatelet medications used to prevent venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), and other thrombotic complications. These drugs are widely applied in perioperative care, cardiovascular disease management, oncology treatment, long-term immobilization, and chronic disease prevention for high-risk patients. By inhibiting coagulation factor activity, reducing platelet aggregation, or regulating coagulation cascade pathways, thromboprophylactic drugs significantly lower the risk of thrombus formation and improve patient outcomes. Current products in the market include low molecular weight heparins, warfarin, direct oral anticoagulants (DOACs), factor Xa inhibitors, and novel targeted anticoagulant therapies. Driven by global population aging, the increasing prevalence of cardiovascular diseases, and the growing adoption of precision anticoagulation strategies, thromboprophylactic therapies are expanding from inpatient applications into long-term outpatient chronic disease management. In recent years, innovations in long-acting formulations, oral therapies, precision medicine, and low-bleeding-risk anticoagulants have accelerated industry transformation, positioning thromboprophylactic drugs as one of the most strategically important segments in the global cardiovascular and chronic disease treatment markets.In 2024, global Thromboprophylactic Drug production reached approximately 197.54 m units, with an average global market price of around US$ 170 perunit.The average gross profit margin of this product is 75%.
Rapid global aging, the rising prevalence of cardiovascular diseases, and the increasing number of minimally invasive surgeries are driving the thromboprophylactic drug market into a long-term expansion cycle. In recent years, growing clinical emphasis on perioperative thrombosis prevention, outpatient anticoagulation management for high-risk patients, and cancer-associated thrombosis prevention has significantly increased the penetration of anticoagulant therapies. Meanwhile, national chronic disease prevention policies, healthcare system reforms, and broader reimbursement coverage are further supporting the standardization of anticoagulation treatment. With the rapid adoption of DOACs, factor Xa inhibitors, and novel targeted anticoagulants, the industry is evolving from traditional injectable therapies toward oral, precision-oriented, and long-term management solutions, creating new growth opportunities for pharmaceutical companies and innovative drug platforms.
Despite strong demand, the Thromboprophylactic Drug market still faces challenges related to bleeding risk management, insufficient long-term patient adherence, and differences in anticoagulation guidelines across countries. Anticoagulant therapy requires a delicate balance between thrombosis prevention and bleeding risk reduction, placing high demands on drug safety profiles and clinical management capabilities. At the same time, innovative anticoagulant drug development involves lengthy R&D cycles, expensive clinical trials, and intense global patent competition, increasing industry entry barriers. In addition, some primary healthcare institutions still lack sufficient anticoagulation monitoring systems, medication management capabilities, and patient education resources, limiting broader adoption of advanced precision anticoagulation solutions. Future market competition will increasingly focus on drug safety, long-term efficacy, and personalized treatment capabilities.
Downstream demand is evolving from traditional inpatient anticoagulation therapy toward long-term chronic disease management, outpatient anticoagulation monitoring, and preventive treatment for high-risk populations. Patients with atrial fibrillation, orthopedic surgery recovery, cancer treatment, and long-term immobilization are generating rapidly increasing demand for long-term anticoagulation management, driving strong growth in oral anticoagulant markets. At the same time, patient demand for greater convenience, improved safety, and reduced monitoring frequency is accelerating the transition toward next-generation oral anticoagulants as mainstream clinical therapies. The development of digital healthcare systems, remote follow-up platforms, and AI-based chronic disease management tools is also transforming anticoagulation treatment from simple medication use into integrated “drug + monitoring + digital health” management ecosystems, further increasing industry value.
The upstream supply chain of the Thromboprophylactic Drug industry mainly includes heparin raw materials, bio-fermentation intermediates, small-molecule APIs, formulation excipients, and advanced pharmaceutical packaging materials. Among these, high-purity anticoagulant active ingredients and sophisticated formulation technologies are the key determinants of drug safety and stability. In recent years, driven by biotechnology upgrades and global supply chain restructuring, demand for high-quality heparin materials, biocatalytic manufacturing processes, and advanced oral anticoagulant APIs has continued to increase. Meanwhile, innovations in sustained-release formulations, targeted drug delivery systems, and novel biological anticoagulant materials are accelerating industry upgrades toward high-end and innovation-driven development. In the future, companies with strong API localization capabilities, global regulatory registration systems, and proprietary anticoagulant technology platforms are expected to establish stronger competitive advantages in the premium thromboprophylactic drug market.
This report studies the global Thromboprophylactic Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Thromboprophylactic Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Thromboprophylactic Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Thromboprophylactic Drug total production and demand, 2021-2032, (K Units)
Global Thromboprophylactic Drug total production value, 2021-2032, (USD Million)
Global Thromboprophylactic Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Thromboprophylactic Drug consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Thromboprophylactic Drug domestic production, consumption, key domestic manufacturers and share
Global Thromboprophylactic Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Thromboprophylactic Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Thromboprophylactic Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Thromboprophylactic Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, Eisai Co Ltd, Sun Pharmaceutical, Teva, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Thromboprophylactic Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Thromboprophylactic Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Thromboprophylactic Drug Market, Segmentation by Type:
Direct Oral Anticoagulants (DOACs)
Low Molecular Weight Heparins (LMWHs)
Vitamin k Antagonists (VKAs)
Factor Xa Inhibitors
Other
Global Thromboprophylactic Drug Market, Segmentation by Mechanism Type:
Anticoagulation
Antiplatelet
Fibrinolytic
Factor Blocking
Global Thromboprophylactic Drug Market, Segmentation by Clinical Application:
DVT Prevention
PE Prevention
Stroke Prevention
Surgical Prophylaxis
Other
Global Thromboprophylactic Drug Market, Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Companies Profiled:
Bristol-Myers Squibb
Bayer
Pfizer
Johnson & Johnson
Sanofi
Boehringer Ingelheim
Daiichi Sankyo
Eisai Co Ltd
Sun Pharmaceutical
Teva
Fresenius
Jingzhou Pharma
Changzhou Qianhong
Viatris
Hepalink
Key Questions Answered:
1. How big is the global Thromboprophylactic Drug market?
2. What is the demand of the global Thromboprophylactic Drug market?
3. What is the year over year growth of the global Thromboprophylactic Drug market?
4. What is the production and production value of the global Thromboprophylactic Drug market?
5. Who are the key producers in the global Thromboprophylactic Drug market?
6. What are the growth factors driving the market demand?

1 Supply Summary
1.1 Thromboprophylactic Drug Introduction
1.2 World Thromboprophylactic Drug Supply & Forecast
1.2.1 World Thromboprophylactic Drug Production Value (2021 & 2025 & 2032)
1.2.2 World Thromboprophylactic Drug Production (2021-2032)
1.2.3 World Thromboprophylactic Drug Pricing Trends (2021-2032)
1.3 World Thromboprophylactic Drug Production by Region (Based on Production Site)
1.3.1 World Thromboprophylactic Drug Production Value by Region (2021-2032)
1.3.2 World Thromboprophylactic Drug Production by Region (2021-2032)
1.3.3 World Thromboprophylactic Drug Average Price by Region (2021-2032)
1.3.4 North America Thromboprophylactic Drug Production (2021-2032)
1.3.5 Europe Thromboprophylactic Drug Production (2021-2032)
1.3.6 China Thromboprophylactic Drug Production (2021-2032)
1.3.7 Japan Thromboprophylactic Drug Production (2021-2032)
1.3.8 India Thromboprophylactic Drug Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Thromboprophylactic Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Thromboprophylactic Drug Major Market Trends
2 Demand Summary
2.1 World Thromboprophylactic Drug Demand (2021-2032)
2.2 World Thromboprophylactic Drug Consumption by Region
2.2.1 World Thromboprophylactic Drug Consumption by Region (2021-2026)
2.2.2 World Thromboprophylactic Drug Consumption Forecast by Region (2027-2032)
2.3 United States Thromboprophylactic Drug Consumption (2021-2032)
2.4 China Thromboprophylactic Drug Consumption (2021-2032)
2.5 Europe Thromboprophylactic Drug Consumption (2021-2032)
2.6 Japan Thromboprophylactic Drug Consumption (2021-2032)
2.7 South Korea Thromboprophylactic Drug Consumption (2021-2032)
2.8 ASEAN Thromboprophylactic Drug Consumption (2021-2032)
2.9 India Thromboprophylactic Drug Consumption (2021-2032)
3 World Manufacturers Competitive Analysis
3.1 World Thromboprophylactic Drug Production Value by Manufacturer (2021-2026)
3.2 World Thromboprophylactic Drug Production by Manufacturer (2021-2026)
3.3 World Thromboprophylactic Drug Average Price by Manufacturer (2021-2026)
3.4 Thromboprophylactic Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Thromboprophylactic Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Thromboprophylactic Drug in 2025
3.5.3 Global Concentration Ratios (CR8) for Thromboprophylactic Drug in 2025
3.6 Thromboprophylactic Drug Market: Overall Company Footprint Analysis
3.6.1 Thromboprophylactic Drug Market: Region Footprint
3.6.2 Thromboprophylactic Drug Market: Company Product Type Footprint
3.6.3 Thromboprophylactic Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 United States VS China VS Rest of the World
4.1 United States VS China: Thromboprophylactic Drug Production Value Comparison
4.1.1 United States VS China: Thromboprophylactic Drug Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Thromboprophylactic Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Thromboprophylactic Drug Production Comparison
4.2.1 United States VS China: Thromboprophylactic Drug Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Thromboprophylactic Drug Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Thromboprophylactic Drug Consumption Comparison
4.3.1 United States VS China: Thromboprophylactic Drug Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Thromboprophylactic Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Thromboprophylactic Drug Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Thromboprophylactic Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Thromboprophylactic Drug Production Value (2021-2026)
4.4.3 United States Based Manufacturers Thromboprophylactic Drug Production (2021-2026)
4.5 China Based Thromboprophylactic Drug Manufacturers and Market Share
4.5.1 China Based Thromboprophylactic Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Thromboprophylactic Drug Production Value (2021-2026)
4.5.3 China Based Manufacturers Thromboprophylactic Drug Production (2021-2026)
4.6 Rest of World Based Thromboprophylactic Drug Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Thromboprophylactic Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Thromboprophylactic Drug Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Thromboprophylactic Drug Production (2021-2026)
5 Market Analysis by Type
5.1 World Thromboprophylactic Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Direct Oral Anticoagulants (DOACs)
5.2.2 Low Molecular Weight Heparins (LMWHs)
5.2.3 Vitamin k Antagonists (VKAs)
5.2.4 Factor Xa Inhibitors
5.2.5 Other
5.3 Market Segment by Type
5.3.1 World Thromboprophylactic Drug Production by Type (2021-2032)
5.3.2 World Thromboprophylactic Drug Production Value by Type (2021-2032)
5.3.3 World Thromboprophylactic Drug Average Price by Type (2021-2032)
6 Market Analysis by Mechanism Type
6.1 World Thromboprophylactic Drug Market Size Overview by Mechanism Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Mechanism Type
6.2.1 Anticoagulation
6.2.2 Antiplatelet
6.2.3 Fibrinolytic
6.2.4 Factor Blocking
6.3 Market Segment by Mechanism Type
6.3.1 World Thromboprophylactic Drug Production by Mechanism Type (2021-2032)
6.3.2 World Thromboprophylactic Drug Production Value by Mechanism Type (2021-2032)
6.3.3 World Thromboprophylactic Drug Average Price by Mechanism Type (2021-2032)
7 Market Analysis by Clinical Application
7.1 World Thromboprophylactic Drug Market Size Overview by Clinical Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Clinical Application
7.2.1 DVT Prevention
7.2.2 PE Prevention
7.2.3 Stroke Prevention
7.2.4 Surgical Prophylaxis
7.2.5 Other
7.3 Market Segment by Clinical Application
7.3.1 World Thromboprophylactic Drug Production by Clinical Application (2021-2032)
7.3.2 World Thromboprophylactic Drug Production Value by Clinical Application (2021-2032)
7.3.3 World Thromboprophylactic Drug Average Price by Clinical Application (2021-2032)
8 Market Analysis by Application
8.1 World Thromboprophylactic Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital Pharmacies
8.2.2 Retail Pharmacies
8.2.3 Online Pharmacies
8.3 Market Segment by Application
8.3.1 World Thromboprophylactic Drug Production by Application (2021-2032)
8.3.2 World Thromboprophylactic Drug Production Value by Application (2021-2032)
8.3.3 World Thromboprophylactic Drug Average Price by Application (2021-2032)
9 Company Profiles
9.1 Bristol-Myers Squibb
9.1.1 Bristol-Myers Squibb Details
9.1.2 Bristol-Myers Squibb Major Business
9.1.3 Bristol-Myers Squibb Thromboprophylactic Drug Product and Services
9.1.4 Bristol-Myers Squibb Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Bristol-Myers Squibb Recent Developments/Updates
9.1.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
9.2 Bayer
9.2.1 Bayer Details
9.2.2 Bayer Major Business
9.2.3 Bayer Thromboprophylactic Drug Product and Services
9.2.4 Bayer Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Bayer Recent Developments/Updates
9.2.6 Bayer Competitive Strengths & Weaknesses
9.3 Pfizer
9.3.1 Pfizer Details
9.3.2 Pfizer Major Business
9.3.3 Pfizer Thromboprophylactic Drug Product and Services
9.3.4 Pfizer Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Pfizer Recent Developments/Updates
9.3.6 Pfizer Competitive Strengths & Weaknesses
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson Details
9.4.2 Johnson & Johnson Major Business
9.4.3 Johnson & Johnson Thromboprophylactic Drug Product and Services
9.4.4 Johnson & Johnson Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Johnson & Johnson Recent Developments/Updates
9.4.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.5 Sanofi
9.5.1 Sanofi Details
9.5.2 Sanofi Major Business
9.5.3 Sanofi Thromboprophylactic Drug Product and Services
9.5.4 Sanofi Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Sanofi Recent Developments/Updates
9.5.6 Sanofi Competitive Strengths & Weaknesses
9.6 Boehringer Ingelheim
9.6.1 Boehringer Ingelheim Details
9.6.2 Boehringer Ingelheim Major Business
9.6.3 Boehringer Ingelheim Thromboprophylactic Drug Product and Services
9.6.4 Boehringer Ingelheim Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Boehringer Ingelheim Recent Developments/Updates
9.6.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.7 Daiichi Sankyo
9.7.1 Daiichi Sankyo Details
9.7.2 Daiichi Sankyo Major Business
9.7.3 Daiichi Sankyo Thromboprophylactic Drug Product and Services
9.7.4 Daiichi Sankyo Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Daiichi Sankyo Recent Developments/Updates
9.7.6 Daiichi Sankyo Competitive Strengths & Weaknesses
9.8 Eisai Co Ltd
9.8.1 Eisai Co Ltd Details
9.8.2 Eisai Co Ltd Major Business
9.8.3 Eisai Co Ltd Thromboprophylactic Drug Product and Services
9.8.4 Eisai Co Ltd Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Eisai Co Ltd Recent Developments/Updates
9.8.6 Eisai Co Ltd Competitive Strengths & Weaknesses
9.9 Sun Pharmaceutical
9.9.1 Sun Pharmaceutical Details
9.9.2 Sun Pharmaceutical Major Business
9.9.3 Sun Pharmaceutical Thromboprophylactic Drug Product and Services
9.9.4 Sun Pharmaceutical Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Sun Pharmaceutical Recent Developments/Updates
9.9.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
9.10 Teva
9.10.1 Teva Details
9.10.2 Teva Major Business
9.10.3 Teva Thromboprophylactic Drug Product and Services
9.10.4 Teva Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Teva Recent Developments/Updates
9.10.6 Teva Competitive Strengths & Weaknesses
9.11 Fresenius
9.11.1 Fresenius Details
9.11.2 Fresenius Major Business
9.11.3 Fresenius Thromboprophylactic Drug Product and Services
9.11.4 Fresenius Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Fresenius Recent Developments/Updates
9.11.6 Fresenius Competitive Strengths & Weaknesses
9.12 Jingzhou Pharma
9.12.1 Jingzhou Pharma Details
9.12.2 Jingzhou Pharma Major Business
9.12.3 Jingzhou Pharma Thromboprophylactic Drug Product and Services
9.12.4 Jingzhou Pharma Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Jingzhou Pharma Recent Developments/Updates
9.12.6 Jingzhou Pharma Competitive Strengths & Weaknesses
9.13 Changzhou Qianhong
9.13.1 Changzhou Qianhong Details
9.13.2 Changzhou Qianhong Major Business
9.13.3 Changzhou Qianhong Thromboprophylactic Drug Product and Services
9.13.4 Changzhou Qianhong Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Changzhou Qianhong Recent Developments/Updates
9.13.6 Changzhou Qianhong Competitive Strengths & Weaknesses
9.14 Viatris
9.14.1 Viatris Details
9.14.2 Viatris Major Business
9.14.3 Viatris Thromboprophylactic Drug Product and Services
9.14.4 Viatris Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Viatris Recent Developments/Updates
9.14.6 Viatris Competitive Strengths & Weaknesses
9.15 Hepalink
9.15.1 Hepalink Details
9.15.2 Hepalink Major Business
9.15.3 Hepalink Thromboprophylactic Drug Product and Services
9.15.4 Hepalink Thromboprophylactic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Hepalink Recent Developments/Updates
9.15.6 Hepalink Competitive Strengths & Weaknesses
10 Industry Chain Analysis
10.1 Thromboprophylactic Drug Industry Chain
10.2 Thromboprophylactic Drug Upstream Analysis
10.2.1 Thromboprophylactic Drug Core Raw Materials
10.2.2 Main Manufacturers of Thromboprophylactic Drug Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Thromboprophylactic Drug Production Mode
10.6 Thromboprophylactic Drug Procurement Model
10.7 Thromboprophylactic Drug Industry Sales Model and Sales Channels
10.7.1 Thromboprophylactic Drug Sales Model
10.7.2 Thromboprophylactic Drug Typical Distributors
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer